A cell-based subretinal implant shows promise in the treatment of geographic atrophy, achieving the unprecedented milestone ...

The global Diabetic Retinopathy Market is valued at USD 9.1 Billion in 2024 and is projected to reach a value of USD 15.1 ...

William Blair initiated coverage of Ocular Therapeutix (OCUL) with an Outperform rating and fair value of $18 per share. Ocular is a commercial ...

The future of eye care holds immense promise, with innovations poised to deliver more accurate, effective, affordable, and ...

DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME) Over 800 patients randomized in DIAMOND-1 or DIAMOND-2 Phase 3 trials at an ...

DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME)Over 800 patients randomized ...

Sound Pharmaceuticals is pleased to announce that it has been invited to present its R&D and financing goals at four upcoming life science and healthcare investor conferences over the next month.

Have you ever noticed unexplained floaters or a slight blurriness in your vision? While these symptoms might seem minor, they ...

Purpose To compare changes in retinal vascular calibre after 2 years of treatment with intravitreal bevacizumab (BVZ) or dexamethasone implant (DEX) in patients with centre-involving diabetic macular ...

William Blair initiated coverage on Ocular Therapeutix (NASDAQ:OCUL) with an Outperform rating, setting a fair value target ...